Literature DB >> 9867216

Inhibition of glucose stimulated insulin secretion by neuropeptide Y is mediated via the Y1 receptor and inhibition of adenylyl cyclase in RIN 5AH rat insulinoma cells.

D G Morgan1, R N Kulkarni, J D Hurley, Z L Wang, R M Wang, M A Ghatei, A E Karlsen, S R Bloom, D M Smith.   

Abstract

Neuropeptide Y (NPY) has been shown to inhibit insulin secretion from the islets of Langerhans. We show that insulin secretion in the insulinoma cell line RIN 5AH is inhibited by NPY. 125I-Peptide YY (PYY) saturation and competition-binding studies using NPY fragments and analogues on membranes prepared from this cell line show the presence of a single class of NPY receptor with a Y1 receptor subtype-like profile. Inhibition of insulin secretion in this cell line by NPY fragments and analogues also shows a Y1 receptor-like profile. Both receptor binding and inhibition of insulin secretion showed the same orders of potency with NPY > [Pro34]-NPY > NPY 3-36 >> NPY 13-36. The Y1 receptor antagonist, BIBP 3226, blocks NPY inhibition of insulin secretion from, and inhibits 125I-PYY binding to, RIN 5AH cells. Northern blot analysis using a Y1-receptor specific probe shows that NPY Y1 receptors are expressed by RIN 5AH cells. Y5 receptors are not expressed in this cell line. Neuropeptide Y inhibition of insulin secretion is blocked by incubation with pertussis toxin, implying that the effect is via a G-protein (Gi or Go) coupled receptor. Neuropeptide Y inhibits the activation of adenylyl cyclase by isoprenaline in RIN 5AH cell lysates, and the stimulation of cAMP by glucagon-like peptide-1 (7-36) amide (GLP-1). It also blocks insulin secretion stimulated by GLP-1, but not by dibutyryl cyclic AMP. Hence, we suggest that NPY inhibits insulin secretion from RIN 5AH cells via a Y1 receptor linked through Gi to the inhibition of adenylyl cyclase.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9867216     DOI: 10.1007/s001250051095

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  18 in total

Review 1.  Osteoblastic Actions of the Neuropeptide Y System to Regulate Bone and Energy Homeostasis.

Authors:  Harry Horsnell; Paul A Baldock
Journal:  Curr Osteoporos Rep       Date:  2016-02       Impact factor: 5.096

2.  NPY receptors as potential targets for anti-obesity drug development.

Authors:  Ernie Yulyaningsih; Lei Zhang; Herbert Herzog; Amanda Sainsbury
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

3.  Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity.

Authors:  D Boey; S Lin; T Karl; P Baldock; N Lee; R Enriquez; M Couzens; K Slack; R Dallmann; A Sainsbury; H Herzog
Journal:  Diabetologia       Date:  2006-04-21       Impact factor: 10.122

Review 4.  The NPY system and its neural and neuroendocrine regulation of bone.

Authors:  Ee Cheng Khor; Paul Baldock
Journal:  Curr Osteoporos Rep       Date:  2012-06       Impact factor: 5.096

5.  Spatial and temporal coordination of insulin granule exocytosis in intact human pancreatic islets.

Authors:  Joana Almaça; Tao Liang; Herbert Y Gaisano; Hong Gil Nam; Per-Olof Berggren; Alejandro Caicedo
Journal:  Diabetologia       Date:  2015-09-16       Impact factor: 10.122

Review 6.  Anorexia in human and experimental animal models: physiological aspects related to neuropeptides.

Authors:  Mitsuhiro Yoshimura; Yasuhito Uezono; Yoichi Ueta
Journal:  J Physiol Sci       Date:  2015-06-30       Impact factor: 2.781

7.  Neuropeptide Y and somatostatin inhibit insulin secretion through different mechanisms.

Authors:  Tara A Schwetz; Alessandro Ustione; David W Piston
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-12-04       Impact factor: 4.310

8.  Comparison of the expression of calcitonin receptor-like receptor (CRLR) and receptor activity modifying proteins (RAMPs) with CGRP and adrenomedullin binding in cell lines.

Authors:  Tejal Choksi; Debbie L Hay; Stephen Legon; David R Poyner; Stefanie Hagner; Stephen R Bloom; David M Smith
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

Review 9.  Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes.

Authors:  Bo Ahrén
Journal:  Nat Rev Drug Discov       Date:  2009-04-14       Impact factor: 84.694

10.  Pancreatic islet neuropeptide Y overexpression has minimal effect on islet morphology and β-cell adaptation to high-fat diet.

Authors:  Yui Machida; Christine Bruinsma; Daniel R Hallinger; Stephen M Roper; Eden Garcia; Michelle B Trevino; Joseph Nadler; Rexford Ahima; Yumi Imai
Journal:  Endocrinology       Date:  2014-10-06       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.